| 41.11 0.17 (0.42%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 51.42  |
1-year : | 53.85 |
| Resists | First : | 44.02 |
Second : | 46.11 |
| Pivot price | 42.55 |
|||
| Supports | First : | 40.65 |
Second : | 33.82 |
| MAs | MA(5) : | 41.74 |
MA(20) : | 43.03 |
| MA(100) : | 43.51 |
MA(250) : | 44.66 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 6.5 |
D(3) : | 7.7 |
| RSI | RSI(14): 31.8  |
|||
| 52-week | High : | 49.91 | Low : | 40.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SNY ] has closed above bottom band by 5.2%. Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.14 - 41.34 | 41.34 - 41.55 |
| Low: | 40.17 - 40.39 | 40.39 - 40.6 |
| Close: | 40.77 - 41.11 | 41.11 - 41.45 |
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
Fri, 25 Sep 2026
Sanofi (SNY) stock price, news, quote and history - Yahoo Finance UK
Fri, 25 Sep 2026
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent - The Globe and Mail
Thu, 24 Sep 2026
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 22 Sep 2026
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine - TradingView
Mon, 21 Sep 2026
Sanofi (SNY) Stock Analysis: Exploring A 26.46% Upside Potential In The Healthcare Sector - DirectorsTalk Interviews
Thu, 17 Sep 2026
20 older drugs and 3 plants may leave Sanofi (SNY). What does it get in return? - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,400 (M) |
| Shares Float | 2,160 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 8 (%) |
| Shares Short | 7,320 (K) |
| Shares Short P.Month | 7,370 (K) |
| EPS | 1.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.31 |
| Profit Margin | 8 % |
| Operating Margin | 21 % |
| Return on Assets (ttm) | 5 % |
| Return on Equity (ttm) | 5.7 % |
| Qtrly Rev. Growth | 14.6 % |
| Gross Profit (p.s.) | 14.97 |
| Sales Per Share | 20.38 |
| EBITDA (p.s.) | 5.64 |
| Qtrly Earnings Growth | -91.2 % |
| Operating Cash Flow | 11,840 (M) |
| Levered Free Cash Flow | 6,300 (M) |
| PE Ratio | 21.86 |
| PEG Ratio | 29.5 |
| Price to Book value | 1.23 |
| Price to Sales | 2.01 |
| Price to Cash Flow | 8.33 |
| Dividend | 2.42 |
| Forward Dividend | 0 |
| Dividend Yield | 5.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|